|
2023–2024 |
Histopathological analysis of a total of 68 mousebrain slides stained for H&E(To provide analysis services by researchers) |
|
2023–2025 |
A multicenter, randomized, open-label, adjustable phase i study to investigate the safety, tolerability, immunogeneticity, pharmacokinetics, and pharmacodynamics of ingredients intravenous doses of glofitamab administered after prior treatment with ocrelizumab in patients with multiple sclerosis |
|
2021–2029 |
|
|
2021–2026 |
A phase 3 randomized double blind study of efficiency and safety for comparison sar442168 with virtual medicine in patients |
|
2020–2024 |
A phase 3 randomized double-blind study of efficacy and safety comperes SAR442168 with placebo in patients with non relapsing SPMS |
|
2020–2024 |
|
|
2020–2024 |
Single, prospective, multicenter, open study to access the efficacy of treatment with ofatumumab those referred to by the patient outcome in patients with relapsing multiple sclerosis switches treatment with dimethyl fumarate or fingolimond |
|
2020–2026 |
Neuroscience and Neurodegeneration. |
|
2020–2023 |
Non-neuronal cellular elements of the central Nervous System and structural biomarkers in a mouse model of Spinal Muscular Atrophy |
|
2020–2023 |
National Research Network for Precision Medicine in Neurodegenerative Diseases |
|
2012–2026 |
Education in neurological diseases |
|
2006–2008 |
Practical training of biology school students |
